Tagged Articles

plaque psoriasis 4 articles

Plaque psoriasis drug approved with strong suicidal ideation warning

The recently approved anti-inflammatory plaque psoriasis drug Siliq (brodalumab) will hit the market later this year facing major hurdles, including a black box warning, restrictive prescribing protocols, and steep competition. The development of Siliq came out of a partnership between Amgen and AstraZeneca. In 2015, Amgen backed out of the deal after observing suicidal ideation in patients who were treated with the drug during clinical trials. Amgen feared the drug would not only have a difficult road to approval due to the suicide risk, if it were approved, it would come with restrictive labeling. AstraZeneca then struck a deal with ... Read More

FDA approves new drug to treat plaque psoriasis

Federal drug regulators have approved Novartis AG’s new drug Cosentyx designed to dramatically improve symptoms of moderate-to-severe plaque psoriasis. The approval gives the Swiss pharmaceutical company first market share against competitors Eli Lilly & Co. and Amgen Inc., both of which are seeking approval for similar treatments. Psoriasis is is a skin condition that causes patches of skin redness and irritation. The most common form of the autoimmune disorder is plaque psoriasis, which causes patients to develop thick, red skin with flaky, silver-white patches called scales. An estimated 7.5 million Americans have psoriasis. Cosentyx contains the active ingredient secukinumab, an ... Read More

Research suggests juvenile arthritis drug may not be cause of cancer

University of Alabama Birmingham (UAB) pharmicoepidemiologist Tim Beukelman and his team of researchers combed through millions of records of children to determine if a life-altering drug for juvenile arthritis, called a TNF-Blocker, could cause cancer. The drugs are considered highly effective for the treatment of inflammation attacks on children’s joints as a result of juvenile arthritis, a condition that can be disabling. However, the medication also carries a black box warning that some lymphomas and other malignancies, some of which were fatal, had been reported in children using the drug. Reports of cancer were enough to result in the boxed ... Read More

Labels on TNFa blockers get stronger warning

The black box warning for a class of immunosuppressant drugs known as Tumor Necrosis Factor-alpha (TNFa) blockers is being updated to include the risk of potentially deadly infections from two bacterial pathogens, Legionella and Listeria. TNFa blockers are biologic products that include Remicade (infliximab), Enbrel (etanercept), Humira (adalimumab), Cimzia (certolizumab pegol), and Simponi (golmumab). TNFa blockers are drugs used to treat Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis, and/or juvenile idiopathic arthritis. Since TNFs blockers are immunosuprresants, patients who take these drugs are at increased risk of serious, including fatal, infections. These infections can involve ... Read More